companydata.dkcompanydata.dk

AGC Biologics A/S: Financial statements 2019

CVR: 25950941

Source: annual report 2019, Danish Business Authority

01/01/2019 – 31/12/2019

AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 996,136,000 and a net result of DKK 154,328,000 compared with DKK 96,167,000 the year before. That is an increase of 43.8% compared with the year before. The profit margin was 15.5%. Equity in the 2019 report amounted to DKK 215,139,000. The solvency ratio was 18.2%. The company had 377 employees in the financial year.

Revenue
DKK 996,136,000
Gross Profit
DKK 257,109,000
Profit/Loss
DKK 154,328,000
Equity
DKK 215,139,000
Total Assets
DKK 1,182,430,000
Employees
377

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2019996.1M257.1M154.3M215.1M377
2018692.6M162.3M96.2M316.8M312
2017643.6M156.8M74.5M290.6M303
2016521.8M116.1M68.2M216.1M245
2015320.5M62.3M8.4M147.9M209

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2019

Ikuo Matsukura leaves the board of AGC Biologics A/SDec 30, 2019

As of December 30, 2019, Ikuo Matsukura has left the board of directors of AGC Biologics A/S.

AGC Biologics A/S: The 2018 annual report is outMay 31, 2019

AGC Biologics A/S has published its annual report for 2018. Revenue came to DKK 692,613,000, and the net result was DKK 96,167,000.

Hideaki Kan joins the board of AGC Biologics A/SFeb 12, 2019

As of February 12, 2019, Hideaki Kan has joined the board of directors of AGC Biologics A/S.

Hideyuki Kurata leaves the board of AGC Biologics A/SJan 31, 2019

As of January 31, 2019, Hideyuki Kurata has left the board of directors of AGC Biologics A/S.

About AGC Biologics A/S

AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.

Source: annual report 2025, Danish Business Authority